Conatus Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2005-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.conatuspharma.com
Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo
- Conditions
- Liver DiseasesDecompensated Non-Alcoholic Steatohepatitis CirrhosisNASH FibrosisOrthotopic Liver TransplantationLiver FibrosisLiver Cirrhosis
- Interventions
- Diagnostic Test: Ultrasound
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Conatus Pharmaceuticals Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03479125
- Locations
- 🇺🇸
Gastro One, Germantown, Tennessee, United States
🇺🇸Inland Empire Liver Foundation, Rialto, California, United States
🇺🇸Options Health Research, LLC, Tulsa, Oklahoma, United States
Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis
- Conditions
- Decompensated Cirrhosis
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Conatus Pharmaceuticals Inc.
- Target Recruit Count
- 210
- Registration Number
- NCT03205345
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Stanford University, Redwood City, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
- Conditions
- Non-alcoholic SteatohepatitisLiver DiseasesFibrosis
- Interventions
- First Posted Date
- 2016-02-19
- Last Posted Date
- 2019-08-19
- Lead Sponsor
- Conatus Pharmaceuticals Inc.
- Target Recruit Count
- 318
- Registration Number
- NCT02686762
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸UCLA The Pfleger Liver Institute, Los Angeles, California, United States
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
- Conditions
- Hepatic CirrhosisPortal HypertensionLiver Cirrhosis
- Interventions
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2016-12-21
- Lead Sponsor
- Conatus Pharmaceuticals Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT02230683
- Locations
- 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸North Shore University Hospital, Manhasset, New York, United States
🇺🇸St. Luke's Health Baylor College of Medicine, Houston, Texas, United States
A Study of IDN-6556 in Subjects With Liver Cirrhosis
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2017-07-05
- Lead Sponsor
- Conatus Pharmaceuticals Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT02230670
- Locations
- 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Cedar-Sinai Medical Center, Los Angeles, California, United States
A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV
- Conditions
- Liver FibrosisHepatic FibrosisLiver CirrhosisHepatic Cirrhosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-05-14
- Last Posted Date
- 2019-12-11
- Lead Sponsor
- Conatus Pharmaceuticals Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT02138253
- Locations
- 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸UCLA Pfleger Liver Institute, Los Angeles, California, United States
🇺🇸Piedmont Atlanta Hospital, Atlanta, Georgia, United States
PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers
- Conditions
- Liver DiseasesHepatic ImpairmentDigestive System Diseases
- Interventions
- First Posted Date
- 2014-04-24
- Last Posted Date
- 2016-02-24
- Lead Sponsor
- Conatus Pharmaceuticals Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT02121860
- Locations
- 🇺🇸
Avail Clinical Research, DeLand, Florida, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases
- Conditions
- Nonalcoholic SteatohepatitisNon-alcoholic Fatty Liver Disease
- Interventions
- Other: Placebo
- First Posted Date
- 2014-03-04
- Last Posted Date
- 2016-08-30
- Lead Sponsor
- Conatus Pharmaceuticals Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT02077374
- Locations
- 🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸Mary Immaculate Hospital, Newport News, Virginia, United States
🇺🇸University of Miami, Miami, Florida, United States
PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers
- Conditions
- Renal InsufficiencyKidney DiseasesRenal ImpairmentKidney Disease
- Interventions
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2016-01-28
- Lead Sponsor
- Conatus Pharmaceuticals Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT02039817
- Locations
- 🇺🇸
Avail Clinical Research, DeLand, Florida, United States
🇺🇸University of Miami, Miami, Florida, United States
Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF
- Conditions
- Acute on Chronic Hepatic FailureLiver CirrhosisAcute Alcoholic HepatitisAcute Liver Failure
- Interventions
- Other: Placebo
- First Posted Date
- 2013-09-09
- Last Posted Date
- 2016-04-11
- Lead Sponsor
- Conatus Pharmaceuticals Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT01937130
- Locations
- 🇬🇧
Derriford Hospital, Plymouth, United Kingdom
🇺🇸Georgetown University Hospital, Washington, District of Columbia, United States
🇬🇧University College London, Royal Free Hospital, London, United Kingdom